Proposal to distinguish HER2-low from HER2-normal breast cancer by in situ hybridisation.
Yen-Ying ChenChing-Fen YangChih-Yi HsuPublished in: Journal of clinical pathology (2022)
:CEP17 ratio higher than the upper bound of the benign glands can be an alternative method.
Keyphrases